Document Detail


Somatropin in adults: new preparation. No benefit.
MedLine Citation:
PMID:  10848047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) Growth hormone deficiency in adults is a poorly defined disease, and its impact in terms of morbidity and mortality is not known. (2) The assessment files on the three somatropin ranges are based on results for nearly 600 adult patients included in placebo-controlled trials. (3) While clinical trials are relatively numerous, their quality is mediocre. Only methodological trickery enabled the authors to elicit significant results using surrogate end points; no benefit of somatropin on tangible clinical criteria has been proven. (4) At the beginning of treatment somatropin frequently has adverse effects linked to water and sodium retention; the risk of severe adverse effects has not been ruled out (diabetogenic or carcinogenic effects). (5) Treatment necessitates chronic daily injections.
Authors:
-
Related Documents :
10718827 - A therapeutic trial of growth hormone in hypopituitary adults and its influence upon co...
22410207 - Contribution of spontaneous improvement to placebo response in depression: a meta-analy...
15799207 - Optimizing somatostatin analog therapy in acromegaly: long-acting formulations.
18302457 - Epidermal growth factor in liposomes may enhance osteoclast recruitment during tooth mo...
20725517 - Are nsaids useful to treat alzheimer's disease or mild cognitive impairment?
15049727 - Adding ultrasound in the management of soft tissue disorders of the shoulder: a randomi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  7     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  1998 Dec 
Date Detail:
Created Date:  2000-05-04     Completed Date:  2000-05-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  172-4     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Clinical Trials as Topic
France
Human Growth Hormone* / administration & dosage,  adverse effects,  deficiency,  therapeutic use
Humans
Hypopituitarism / diagnosis,  drug therapy*
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biogenetic glucagon: new preparation. Four times more expensive for the same service.
Next Document:  Benazepril and the kidney: new indication. No better than the other ACE inhibitors.